Table 3 |
|||
|
Proportion of households that had at least one minor adverse event. |
|||
|
Survey Round |
DuraNet (%) |
Olyset (%) |
PermaNet (%) |
|
|
|||
|
Round 1: (Short-term trial of LLINs) |
88.6 |
24.2 |
5.7 |
|
|
|||
|
Round 2: (Short-term trial of LLINs) |
56.3 |
5.7 |
3.0 |
|
|
|||
|
Round 3: (Longer-term trial of LLINs) |
16.7 |
0 |
0 |
|
|
|||
|
Atkinson et al. Malaria Journal 2009 8:298 doi:10.1186/1475-2875-8-298 |
|||
